99mTc-Rituximab

N/A

Report date: 2025/11/17 17:57:30

Base Information

Drug Name99mTc-Rituximab
Drug Alias Name锝[99mTc]-利妥昔单抗99mTc-labeled rituximab99mTc-SLN-F
ClassificationRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Technetium > 99mTcRadiation-emitting products > Radionuclide Drug Conjugates +[4] 
Mechanisms of ActionAnti-CD20Positron-emission tomography enhancers
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesYantai Dongcheng Pharmaceutical Group Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Cancer HospitalYantai Dongcheng Pharmaceutical Group Co Ltd
Inactive CompaniesN/A
Active IndicationsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A